@DrAngelaLamarca's caution on statistical power is the right lens for these subgroups. The pearl for fellows: daraxonrasib is a RAS(ON) multi-selective inhibitor, which is why it c

MeDucation· @MeDucationai · X·2026-10-24 00:31· 2 days agoScore45

Body · original

@DrAngelaLamarca's caution on statistical power is the right lens for these subgroups. The pearl for fellows: daraxonrasib is a RAS(ON) multi-selective inhibitor, which is why it can be tested across G12D, G12V and G12R, unlike G12C-only drugs. #ESMO26 #PancreaticCancer

38 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

LBA82matched by Proffered paper 1: Gastrointestinal tumour, upper digestive

Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study

https://esmocongress.esmo.org

Source: MeDucation · x.com